anti-inflammatory cytokines

Overview

Anti-inflammatory cytokines are a class of immunoregulatory signaling proteins that function to dampen, resolve, or counterbalance inflammatory responses initiated by pro-inflammatory cytokines such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). The most extensively studied member of this group is interleukin-10 (IL-10), alongside transforming growth factor-beta (TGF-β), interleukin-4 (IL-4), interleukin-13, and interleukin-21. These molecules operate through a network of receptor-mediated signaling cascades — including the JAK2/STAT3 signaling pathway and PI3K/Akt signaling pathway — to modulate immune cell activation, macrophage polarization, and tissue repair. Their physiological roles span the resolution of acute inflammation, maintenance of immune homeostasis, and protection of tissues from immune-mediated damage across virtually every organ system.

The balance between pro-inflammatory and anti-inflammatory cytokines is a critical determinant of disease outcome in a broad spectrum of conditions, including autoimmune disorders, metabolic diseases, neurodegenerative conditions, and cancer. Dysregulation of this balance — particularly a deficiency in anti-inflammatory cytokine signaling — is associated with chronic inflammatory pathologies such as inflammatory bowel disease, rheumatoid arthritis, psoriatic arthritis, and cardiovascular disease. As a result, strategies to restore or amplify anti-inflammatory cytokine activity, whether through exogenous delivery, pharmacological induction, or cellular reprogramming, represent a major focus of contemporary biomedical research.

Focus of Latest Publications

Recent publications have examined anti-inflammatory cytokines, especially interleukin-10 (IL-10), in diverse inflammatory and regenerative settings. In severe traumatic brain injury, early inflammatory mediator profiling in plasma and cerebrospinal fluid showed that IL-10 was consistently elevated alongside IL-6 and IL-8 during the first week after injury, with particularly marked compartmentalized changes in cerebrospinal fluid. In the same study, IL-10 measurements were compared across electrochemiluminescence and proximity extension assay platforms, and the two methods showed strong correlation for IL-10 but limited interchangeability overall.

Several studies linked IL-10 to therapeutic modulation of inflammation. In a mouse model of repetitive mild traumatic brain injury, intranasal mRNA-loaded lipid nanoparticles co-delivering brain-derived neurotrophic factor and IL-10 reduced neuroinflammation, inhibited neuronal death, and improved cognition. In acute lung injury, a lung-targeted lipid nanoparticle platform delivered IL-10 mRNA and significantly reduced the inflammatory response. In myocardial infarction, a spatiotemporally orchestrated microneedle patch used adeno-associated virus-mediated IL-10 delivery during the remodeling phase to suppress aberrant fibroblast activation and limit fibrosis, complementing an early magnesium-loaded nanoparticle module aimed at the inflammatory phase.

IL-10 also appeared in studies of tissue repair and immune regulation. In diabetic and infected wound models, biomaterial-based hydrogels promoted healing in part by increasing IL-10 and shifting macrophages toward reparative phenotypes, while reducing pro-inflammatory mediators such as TNF-α and IL-6. A dual-crosslinked hydrogel for diabetic chronic wounds downregulated TNF-α and IL-6 and upregulated IL-10, and a conductive exosome-loaded hydrogel with electrical stimulation similarly upregulated IL-10 to drive M2 polarization and alleviate inflammation. In women with breast cancer receiving chemotherapy, strength training was associated with changes in serum cytokines including IL-10, although no significant group-by-time interaction was reported and the clinical significance remained uncertain.

Other publications used IL-10 as a biomarker or part of broader cytokine profiling. In monozygotic twins discordant for pain-related temporomandibular disorder, plasma IL-10 was measured together with IL-6, and the IL-6/IL-10 ratio differed within twin pairs, contributing to an inflammatory-oxidative profile associated with pain. In cervical cancer progression, IL-10 expression was evaluated alongside TNF-α, IL-6, IL-8, and VEGF across weight categories. In vitreoretinal lymphoma, elevated intraocular IL-10 was noted as an established biomarker, and the first vitreous detection of IL-16 was reported as a potential additional indicator.

Key Publications

• NEWJun A Dynamic and Complex Early Inflammatory Response in Blood and Cerebrospinal Fluid of Severe Traumatic Brain Injury Patients: A Dual Platform Analysis. (Inflammation, 2026, PMID 42360398): "Key mediators (IL-6, IL-8, IL-10) were consistently elevated in both compartments."
• NEWJul The Effect of Strength Training During Chemotherapy in Women With Breast Cancer on Serum Cytokine Concentrations and Skeletal Muscle Autophagy-Related Proteins. (European journal of sport science, 2026, PMID 42350900): "Serum cytokines (IFN-γ, IL-1RA, IL-6, IL-8, IL-10, IL-17, MCP-1, TNF-α) were quantified, and muscle biopsies were analyzed for autophagy- and heat-shock-related proteins."
• NEWJun IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy. (Journal for immunotherapy of cancer, 2026, PMID 42331382): "IL-10 secretion by CD8 T cells orchestrates early NK cell recruitment and antitumor immunity after anti-VEGFR-2/PD-1 therapy."
• May Nose-to-Brain Delivery of mRNA-Loaded Lipid Nanoparticles Bypasses the Blood-Brain Barrier for Effective Brain Disease Therapy. (ACS nano, 2026, PMID 42157518): "Co-delivery of mRNAs encoding brain-derived neurotrophic factor (BDNF) and interleukin-10 (IL-10) using INBT LNPs significantly reduced neuroinflammation, inhibited neuronal death, and improved cognition in a repetitive mild traumatic brain injury (rmTBI) mouse model."
• May Optimization of Lipid Nanoparticles for Safe and Versatile Lung-Targeted RNA Delivery and Disease Therapy. (ACS nano, 2026, PMID 42138142): "Further validation is provided in an acute lung injury (ALI) model, where the delivery of IL-10 mRNA significantly reduces the inflammatory response."
• May Inflammatory, oxidative, and neurotrophic profiles in monozygotic twins discordant for pain-related TMD. (Molecular biology reports, 2026, PMID 42132960): "Significant within-pair differences were identified in IL-6, IL-6/IL-10 ratio, MDA/SOD ratio, MMP-9, TIMP-2, and BDNF levels."
• Jun ZnO-integrated konjac glucomannan/Bletilla striata hydrogel with antibacterial, anti-inflammatory, and pro-angiogenic properties for accelerated infected wound healing. (International journal of biological macromolecules, 2026, PMID 42103129): "the hydrogel effectively suppressed chronic inflammation by modulating the TNF-α/NF-κB and IL-10 signaling axes while significantly promoting functional angiogenesis and organized collagen deposition."
• Jun Organic-inorganic dual-crosslinked hydrogel with extracellular matrix biomimetic and immune regulation for diabetic chronic wound healing. (International journal of biological macromolecules, 2026, PMID 42067094): "by shifting macrophage polarization toward a reparative phenotype, via downregulation of TNF-α and IL-6 and upregulation of IL-10."
• May Obesity and Pro-Inflammatory Cytokines: Gene Expression Patterns Within Cervical Cancer Progression. (In vivo (Athens, Greece), 2026, PMID 42049436): "This study aimed to evaluate the gene expression levels of TNF-α, IL-6, IL-8, IL-10, and VEGF during CC progression in patients across different weight categories: normal weight, overweight, and obese."
• May Spatiotemporally Orchestrated Cardiac Microneedle Patch Modulates Post-Infarction Immunity and Fibrosis. (ACS nano, 2026, PMID 42007921): "...enabling adeno-associated virus-mediated interleukin-10 delivery to suppress aberrant fibroblast activation and limit pathological fibrosis during the remodeling phase."